Original Article
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. Aug 21, 2012; 18(31): 4118-4126
Published online Aug 21, 2012. doi: 10.3748/wjg.v18.i31.4118
Figure 3
Figure 3 Effects of MK615 in patients with liver disorder, chronic hepatitis C and non-alcoholic fatty liver disease. A: Alanine aminotransferase (ALT); B: Aspartate aminotransferase (AST); C: Chronic hepatitis C group (ALT); D: Non-alcoholic fatty liver disease group (ALT). aP < 0.05 vs 0 wk group. Dunnett’s test.